Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 13
- Registration Number
- NCT01382212
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2011-04-26
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 255
- Registration Number
- NCT01341782
- Locations
- 🇯🇵
Site Reference ID/Investigator# 53485, Aichi, Japan
🇯🇵Site Reference ID/Investigator# 54387, Sakai, Japan
🇯🇵Site Reference ID/Investigator# 52748, Osaka, Japan
Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Peter Rossing
- Target Recruit Count
- 48
- Registration Number
- NCT01331317
- Locations
- 🇩🇰
Steno Diabetes Center A/S, Gentofte, Denmark
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Ural State Medical University
- Target Recruit Count
- 109
- Registration Number
- NCT01265615
- Locations
- 🇷🇺
Ural Institute of Cardiology, Yekaterinburg, Russian Federation
🇳🇱De Haar Research Foundation, Rotterdam, South Holland, Netherlands
Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2013-02-22
- Target Recruit Count
- 43
- Registration Number
- NCT01220050
- Locations
- 🇮🇹
Mario Negri Institute - Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Danderyd Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01204528
- Locations
- 🇸🇪
Karolinska Institute at Danderyd University Hospital, Danderyd, Stockholm, Sweden
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 2
- Registration Number
- NCT01197664
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 16
- Registration Number
- NCT01163162
- Locations
- 🇺🇸
Roudebush VA Medical Center, Indianapolis, Indiana, United States
Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Kerstyn C. Zalesin, M.D.
- Target Recruit Count
- 49
- Registration Number
- NCT01138475
- Locations
- 🇺🇸
William Beaumont Health Center, Royal Oak, Michigan, United States
Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Erling Bjerregaard Pedersen
- Target Recruit Count
- 30
- Registration Number
- NCT01136564
- Locations
- 🇩🇰
Department of Medical Research, Holstebro, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.